H. Lundbeck Investor Relations Material

H. Lundbeck A/S develops, manufactures, and sells pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, the United States, Canada, and internationally. The company offers psychiatric products, including Abilify Maintena for maintenance treatment of adults with bipolar I disorder or schizophrenia; Risperdal Consta for maintenance treatment of schizophrenia; Vraylar/Lenvima/Xalkori for treating schizophrenia in various countries; Brintellix/Trintellix for treating major depressive disorder; and Rexulti/Brexiprazole as adjunctive therapy with antidepressants in treating adult patients with major depressive disorder. The company was founded in 1915 and is headquartered in Valby, Denmark.